Skip to Main Content
Table 5.

Joint effects of CYP1A2*1F and CYP1A1*2A, CYP1B1 Leu432Val, AHRArg554Lys, CYP3A4*1B, COMTVal158Met and SULT1A1Arg213His on breast cancer risk

AA
AC
CC
n*OR (95% CI)nOR (95% CI)nOR (95% CI)
CYP1A1*2A        
    TT 279/224 1.0 375/376 0.8 (0.6-1.0) 82/112 0.7 (0.5-1.0) 
    TC 259/274 0.9 (0.7-1.1) 220/236 0.8 (0.6-1.1) 6/10 0.5 (0.2-1.3) 
    CC 92/107 0.8 (0.6-1.1) 8/8 0.7 (0.3-2.0) 1/0 — 
    Pinteraction    0.64   
CYP1B1 Leu432Val       
    LL 274/237 1.0 267/237 0.8 (0.6-1.1) 35/33 0.9 (0.5-1.5) 
    LV 240/247 0.9 (0.7-1.1) 211/225 0.8 (0.6-1.1) 35/47 0.6 (0.4-1.1) 
    VV 116/121 0.9 (0.7-1.3) 125/158 0.8 (0.6-1.1) 19/42 0.5 (0.3-0.9) 
    Pinteraction    0.75   
AHR       
    RR 368/375 1.0 303/318 0.9 (0.7-1.1) 40/54 0.8 (0.5-1.2) 
    RL 206/168 1.3 (1.0-1.7) 223/226 1.0 (0.7-1.3) 30/54 0.6 (0.4-1.0) 
    LL 56/62 0.8 (0.6-1.3) 77/76 0.9 (0.7-1.4) 19/14 1.4 (0.7-2.8) 
    Pinteraction    0.13   
CYP3A4*1B       
    AA 537/461 1.0 469/439 0.8 (0.7-1.0) 63/76 0.7 (0.5-1.0) 
    AG 67/106 0.8 (0.5-1.1) 81/120 0.8 (0.6-1.2) 13/26 0.6 (0.3-1.2) 
    GG 26/38 0.9 (0.5-1.6) 53/61 1.1 (0.7-1.8) 13/20 0.8 (0.4-1.8) 
    Pinteraction    0.54   
COMT Val158Met       
    Val/Val 242/248 1.0 239/245 0.9 (0.7-1.2) 33/49 0.7 (04.-1.1) 
    Val/Met 300/264 1.1 (0.8-1.4) 273/281 0.9 (0.7-1.1) 41/59 0.7 (0.5-1.1) 
    Met/Met 88/93 0.9 (0.6-1.3) 91/94 0.8 (0.6-1.2) 15/14 1.0 (0.5-2.2) 
    Pinteraction    0.71   
SULT1A1 Arg213His       
    Arg/Arg 376/335 1.0 364/356 0.9 (0.7-1.1) 51/82 0.6 (0.4-0.9) 
    Arg/His 195/219 0.8 (0.6-1.1) 192/216 0.8 (0.6-1.0) 30/36 0.8 (0.5-1.4) 
    His/His 59/51 1.0 (0.7-1.6) 47/48 0.8 (0.5-1.3) 8/4 2.1 (0.6-7.2) 
    Pinteraction    0.22   
AA
AC
CC
n*OR (95% CI)nOR (95% CI)nOR (95% CI)
CYP1A1*2A        
    TT 279/224 1.0 375/376 0.8 (0.6-1.0) 82/112 0.7 (0.5-1.0) 
    TC 259/274 0.9 (0.7-1.1) 220/236 0.8 (0.6-1.1) 6/10 0.5 (0.2-1.3) 
    CC 92/107 0.8 (0.6-1.1) 8/8 0.7 (0.3-2.0) 1/0 — 
    Pinteraction    0.64   
CYP1B1 Leu432Val       
    LL 274/237 1.0 267/237 0.8 (0.6-1.1) 35/33 0.9 (0.5-1.5) 
    LV 240/247 0.9 (0.7-1.1) 211/225 0.8 (0.6-1.1) 35/47 0.6 (0.4-1.1) 
    VV 116/121 0.9 (0.7-1.3) 125/158 0.8 (0.6-1.1) 19/42 0.5 (0.3-0.9) 
    Pinteraction    0.75   
AHR       
    RR 368/375 1.0 303/318 0.9 (0.7-1.1) 40/54 0.8 (0.5-1.2) 
    RL 206/168 1.3 (1.0-1.7) 223/226 1.0 (0.7-1.3) 30/54 0.6 (0.4-1.0) 
    LL 56/62 0.8 (0.6-1.3) 77/76 0.9 (0.7-1.4) 19/14 1.4 (0.7-2.8) 
    Pinteraction    0.13   
CYP3A4*1B       
    AA 537/461 1.0 469/439 0.8 (0.7-1.0) 63/76 0.7 (0.5-1.0) 
    AG 67/106 0.8 (0.5-1.1) 81/120 0.8 (0.6-1.2) 13/26 0.6 (0.3-1.2) 
    GG 26/38 0.9 (0.5-1.6) 53/61 1.1 (0.7-1.8) 13/20 0.8 (0.4-1.8) 
    Pinteraction    0.54   
COMT Val158Met       
    Val/Val 242/248 1.0 239/245 0.9 (0.7-1.2) 33/49 0.7 (04.-1.1) 
    Val/Met 300/264 1.1 (0.8-1.4) 273/281 0.9 (0.7-1.1) 41/59 0.7 (0.5-1.1) 
    Met/Met 88/93 0.9 (0.6-1.3) 91/94 0.8 (0.6-1.2) 15/14 1.0 (0.5-2.2) 
    Pinteraction    0.71   
SULT1A1 Arg213His       
    Arg/Arg 376/335 1.0 364/356 0.9 (0.7-1.1) 51/82 0.6 (0.4-0.9) 
    Arg/His 195/219 0.8 (0.6-1.1) 192/216 0.8 (0.6-1.0) 30/36 0.8 (0.5-1.4) 
    His/His 59/51 1.0 (0.7-1.6) 47/48 0.8 (0.5-1.3) 8/4 2.1 (0.6-7.2) 
    Pinteraction    0.22   

Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval.

*

No. cases/no. controls. Numbers of subjects vary due to missing information.

OR (95% CIs) adjusted for age at blood draw, age at menarche, parity and age at first birth.

P value derived from a likelihood ratio test comparing a model with main effects for the CYP1A2*1F genotype and the risk factor, and a model with main effects and interaction terms.

Close Modal

or Create an Account

Close Modal
Close Modal